Every 8-K that Immunic, Inc. (IMUX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMUX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMUX filings page.
IMMUNIC, INC. (IMUX) reported that on September 10, 2026, Dr. Duane Nash resigned as a member of its Board of Directors. The company stated that Dr. Nash’s resignation was not due to any disagreement regarding its operations, policies, or practices. Following his resignation, the Board, by resolution, reduced its size from ten members to nine members.
IMMUNIC, INC. (IMUX) announced that it is hosting a Relapsing Multiple Sclerosis Research and Development Day webinar on September 9, 2026, from 11:00 a.m. to 12:30 p.m. Eastern Time, where management will present updates on its programs, including vidofludimus calcium.
The company is using an investor presentation for this event, furnished as Exhibit 99.1. The materials are provided under a Regulation FD disclosure framework and are expressly stated as being furnished, not filed, and therefore are not subject to certain Exchange Act liabilities nor automatically incorporated into other SEC filings.
Immunic also includes an extensive cautionary note that characterizes statements about strategy, clinical development plans, timing of trials and regulatory approvals, cash runway, Nasdaq listing, and capitalization as forward-looking statements subject to substantial risks and uncertainties, directing investors to previously filed Risk Factors for more detail.
Immunic, Inc. reported second quarter 2026 results, board changes and leadership transitions while advancing its multiple sclerosis pipeline. For the quarter ended June 30, 2026, total operating expenses were $35.3 million, driven by research and development of $25.9 million and general and administrative costs of $9.4 million, both higher than the prior-year period due largely to increased personnel and non-cash stock compensation and NDA-supporting studies. Net loss was $34.1 million (basic and diluted loss of $0.80 per share).
Cash and cash equivalents were $155.1 million as of June 30, 2026, and the company expects this to fund operations into late 2027. Clinically, Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track with top-line data expected by the end of 2026, and a Phase 3 trial in progressive MS is planned to start later in 2026. Governance updates include the appointment of Elena Ridloff to the board, with an inaugural option grant for 50,740 shares, and the resignation and separation of former CEO Dr. Daniel Vitt, who moves to a consulting role and Chair of the Scientific Advisory Board under a detailed severance and consulting arrangement.
Immunic, Inc. reports that on July 14, 2026 it made an updated corporate presentation available on its website, also provided as Exhibit 99.1. The materials are furnished under Regulation FD and are expressly not deemed “filed” or incorporated into other securities law filings unless specifically referenced.
The presentation contains extensive forward-looking statements about Immunic’s strategy, cash runway, clinical development of vidofludimus calcium, potential phase 3 plans in progressive multiple sclerosis, regulatory milestones, Nasdaq listing status, and capital structure. Immunic highlights substantial risks and uncertainties and directs readers to the Risk Factors section of its Form 10-K for the year ended December 31, 2025 and subsequent SEC reports.
Immunic, Inc. reported a board change linked to retirement plans. On June 29, 2026, director Tamar Howson resigned from the Board and its Compensation Committee as she transitions into retirement. The company states her resignation did not result from any disagreement over operations, policies, or practices.
Following a recommendation from the Nominating and Corporate Governance Committee, the Board appointed Chief Executive Officer Erik Lundgren as a Class II director, effective July 5, 2026. He will serve until the 2028 annual meeting of stockholders. Lundgren will receive no additional compensation for board service, has not joined any board committee, and aside from his existing employment agreement and CEO compensation, the filing notes no related-party transactions requiring disclosure.
Immunic, Inc. reported results from its annual stockholder meeting. Stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing shares authorized for issuance under the plan by 6,000,000 to a total of 8,644,887 common shares. This expands the pool available for employee and director equity awards.
Three Class III directors – Michael Bonney, Thorvald Nagel and Richard Rudick – were elected to serve until the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Immunic, Inc. filed a current report describing new clinical data it is presenting from the phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis at the 2026 CMSC meeting. The company issued a press release and posted three posters covering efficacy methodology, patient-reported outcomes and safety.
A late-breaking poster introduces a unified Confirmed Disability Change endpoint that combines confirmed disability worsening and improvement; across three statistical models, results favored vidofludimus calcium over placebo. Another poster shows similar changes in depressive-symptom scores between groups through 120 weeks, with numerically higher patient-reported treatment effectiveness for vidofludimus calcium.
Safety data from 467 patients treated up to 120 weeks show comparable overall adverse event, discontinuation and serious adverse event rates between vidofludimus calcium and placebo, supporting a favorable tolerability profile. Vidofludimus calcium remains an investigational oral therapy in late-stage trials for multiple sclerosis.
Immunic, Inc. has appointed biopharmaceutical executive Erik Lundgren as Chief Executive Officer effective May 22, 2026, with employment beginning June 1, 2026, succeeding Daniel Vitt, Ph.D., who remains on the Board and continues to lead scientific strategy and portfolio advancement.
Lundgren’s employment agreement provides a yearly base salary of $685,000, eligibility for a yearly bonus of at least 60% of base salary, and a guaranteed full-year 2026 bonus at not less than that level, paid in six monthly installments of $68,500 each. He may receive an additional $200,000 cash bonus if the pending phase 3 trial for relapsing multiple sclerosis supports a New Drug Application and he remains employed through March 31, 2027, plus a separate $250,000 cash bonus within one month of the effective date.
Severance protections include lump-sum payments and equity vesting enhancements if he is terminated without cause, resigns for Good Reason, or is not renewed, with richer benefits during a Change of Control Period. The Compensation Committee also granted Lundgren an option to purchase 1,000,000 shares of common stock under the 2026 Inducement Equity Compensation Plan, with 25% vesting on the one-year anniversary of May 22, 2026 and the remainder vesting monthly over 36 months at an exercise price equal to the closing stock price on the approval date.
Immunic, Inc. appointed Michael W. Bonney as Chair of its Board of Directors, effective May 16, 2026. Bonney brings more than three decades of biopharmaceutical leadership, including CEO experience at Cubist Pharmaceuticals and senior commercial roles involved in launching Avonex for multiple sclerosis.
In connection with his appointment, he received options to purchase up to 100,000 shares of Immunic common stock, vesting monthly over three years at an exercise price equal to the May 15, 2026 Nasdaq closing price, subject to shareholder approval of an increase in the 2019 Omnibus Equity Incentive Plan share reserve. Simona Skerjanec will transition from Interim Chairperson to continue as a director, and the Board size increases from nine to ten members. Immunic highlights its late-stage program vidofludimus calcium, currently in phase 3 trials in relapsing multiple sclerosis, with top-line data expected by the end of 2026.
Immunic, Inc. reported first quarter 2026 results and highlighted a large private financing to fund its multiple sclerosis programs. For the three months ended March 31, 2026, the company recorded a net loss of $32,588 thousand, driven by research and development expenses of $25,626 thousand and general and administrative expenses of $7,609 thousand.
In February, Immunic closed an oversubscribed private placement of up to $400 million in gross proceeds, with $200 million received upfront, which management expects to fund operations through completion of the phase 3 ENSURE trials in relapsing multiple sclerosis and a planned RMS New Drug Application submission in mid-2027. Cash and cash equivalents increased to $186,629 thousand as of March 31, 2026, and total stockholders’ equity improved to $151,233 thousand, reflecting the new capital despite ongoing operating losses.
Immunic, Inc. appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer effective April 24, 2026, succeeding co-founder Andreas Muehler, M.D., M.B.A., who resigned as CMO and will transition to a consulting role.
Dr. Panzara brings more than 25 years of neurology drug development experience from Neurvati, Wave Life Sciences, Sanofi Genzyme and Biogen, including work on several approved multiple sclerosis therapies. His employment terms include a $600,000 annual base salary, a target bonus of at least 50% of base salary, a $125,000 signing bonus and stock options to purchase 300,000 shares that vest over three years. Dr. Muehler will receive 12 months of base-salary severance from both Immunic and Immunic AG, full vesting of outstanding equity awards and a 10‑month consulting arrangement at $10,000 per month.
Immunic, Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026. Every 10 existing shares will be combined into 1 new share, reducing issued and outstanding shares from approximately 136 million to approximately 13.6 million, without changing the number of authorized shares or par value.
The split is intended primarily to allow Immunic to meet contractual obligations under a securities purchase agreement dated February 12, 2026. All stock options, warrants, restricted stock units and similar securities will be proportionally adjusted in share number and exercise price. No fractional shares will be issued; instead, the transfer agent will aggregate fractional interests, sell the resulting whole shares on the open market and distribute each stockholder’s cash share of the proceeds. Trading on the Nasdaq Capital Market under the symbol IMUX will continue, using a new CUSIP number 4525EP200 for the split-adjusted stock starting April 27, 2026.
Immunic, Inc. reported that stockholders approved a proposal authorizing its board to implement a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-30. Of 130,464,825 shares outstanding on the record date, 70,622,667 shares, or about 54.1%, were represented at the special meeting.
Stockholders supported the proposal with 57,404,749 votes for, 12,594,555 against, and 623,363 abstentions. Following this approval, the board chose a 1-for-10 reverse stock split, expected to become effective at 12:01 a.m. Eastern Time on April 27, 2026, with the post-split shares trading on the Nasdaq Capital Market under the IMUX symbol.
Immunic, Inc. has signed a Retention Bonus Agreement with Chief Executive Officer Daniel Vitt as it begins a search for a new CEO. If he remains employed through the ninety-first day after a new CEO is hired, he will receive a $670,000 cash retention bonus.
The bonus is generally payable in a lump sum after this retention date, or within five days if Immunic terminates him without Cause or he resigns for Good Reason before then. Any bonus paid will be credited against future cash severance, and both parties agreed to mutual non-disparagement under New York law.
Immunic, Inc. announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market. Nasdaq confirmed that the company’s common stock closed at or above $1.00 per share for 20 consecutive business days from February 27, 2026 to March 26, 2026, and the matter is now closed.
The company is a late-stage biotechnology business focused on novel oral therapies for neurologic diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, and is supported by earlier phase 2 results in multiple sclerosis and other conditions.
Immunic, Inc. has appointed veteran biopharmaceutical executive Jon Congleton to its board of directors, effective March 27, 2026, as a Class II director with a term running until the 2028 annual meeting. He will also chair the board’s Compensation Committee, adding extensive CNS and multiple sclerosis commercialization experience to the company’s governance.
In connection with his appointment, Congleton received stock options to purchase 500,000 shares of common stock, vesting monthly over three years at an exercise price equal to the March 27, 2026 Nasdaq closing price, subject to shareholder approval of an increase in shares reserved under Immunic’s 2019 Omnibus Equity Incentive Plan. The board size increased from eight to nine directors. Immunic highlights Congleton’s nearly 40-year biopharma background and notes its lead MS asset, vidofludimus calcium, is in phase 3 trials with top-line data expected by the end of 2026.
Immunic, Inc. reported a 2025 net loss of $97.2M, slightly improved from $100.5M in 2024, as operating expenses rose modestly to $103.2M driven mainly by research and development spending of $82.0M.
The company highlighted an oversubscribed private placement of up to $400M in gross proceeds, including $200M already raised, which it expects to fund completion of phase 3 ENSURE trials in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive multiple sclerosis and begin building a commercial organization. Management expects ENSURE top-line data by the end of 2026, a planned RMS NDA submission in the United States in mid-2027, and is targeting a potential regulatory approval date in 2028.
Immunic, Inc. plans an oversubscribed private placement providing upfront gross proceeds of USD 200 million, with additional potential proceeds of up to USD 200 million through warrant exercises, for total financing of up to USD 400 million. The company will issue 229,076,000 pre-funded warrants at $0.873 each and matching warrants to purchase up to 229,076,000 common shares at an exercise price of $0.873 per share, expiring the earlier of 30 days after topline Phase 3 ENSURE data or February 17, 2031.
Immunic expects this capital, together with existing cash, to fund operations to late 2027, including completion of Phase 3 ENSURE trials in relapsing multiple sclerosis, initiation of a Phase 3 trial in primary progressive multiple sclerosis, and preparation for commercialization of vidofludimus calcium. Separately, the company agreed to cancel 51,087,000 previously issued Series B warrants in exchange for a right to an aggregate 5% royalty on future vidofludimus calcium net sales, leaving 35,579,667 Series B warrants outstanding.
The company will seek stockholder approval for a reverse stock split at a ratio of at least 10:1. Governance changes include appointing BVF principal Thor Nagel to the board, elevating Simona Skerjanec to interim Chairperson, and the resignation of director Maria Törnsén, which was not due to any disagreement with the company.
Immunic, Inc. is moving its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of business on January 7, 2026, while continuing to trade under the symbol IMUX.
The company previously fell out of compliance with Nasdaq’s $1.00 minimum bid price rule and did not regain compliance by the initial December 24, 2025 deadline, triggering this transfer request. With Nasdaq’s approval, Immunic now has an additional 180 days, until June 22, 2026, for its common stock to maintain a minimum $1.00 bid price for at least 10 consecutive business days to regain compliance. As a condition of this extension, Immunic has notified Nasdaq that it will seek to implement a reverse stock split, if needed, and faces potential delisting if compliance is not achieved and any subsequent appeal is unsuccessful.
Immunic, Inc. furnished a current report to note that it has issued a press release announcing its financial results for the quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1 to the report, but the company specifies that this information is being furnished, not filed, so it is not subject to certain liability provisions of the securities laws or automatically incorporated into other SEC filings.
Immunic, Inc. announced presentations of vidofludimus calcium data at the 41st ECTRIMS congress in Barcelona, held September 24-26, 2025. The company issued a press release dated September 25, 2025, and posted a corporate presentation on its website on September 24, 2025, which includes new data from the Phase 2 CALLIPER trial in progressive multiple sclerosis. The filing lists the press release and the presentation as exhibits and states the report was signed by CEO Daniel Vitt.
Immunic (Nasdaq: IMUX) disclosed that it received a Nasdaq bid-price deficiency notice after its shares closed below $1.00 for 30 consecutive trading days, violating Listing Rule 5450(a)(1).
The company has 180 calendar days, until December 24 2025, to regain compliance by posting a closing bid of at least $1.00 for ten consecutive business days. If unsuccessful, Immunic may seek a second grace period or effect a reverse stock split; failure would result in delisting.
The notice does not immediately affect the stock’s listing on the Nasdaq Global Select Market. Management is monitoring the price and evaluating options.